PHILADELPHIA, PA — Virion Therapeutics, LLC announced M. Michelle Berrey, M.D., M.P.H. and Williamson “Bill” Bradford, M.D., Ph.D. have joined the Company’s Board of Directors. In addition, Dr. Teresa Wright has notified the company of her decision to not seek an additional term on the Board.
Andrew Luber, Pharm.D., President and Chief Executive Officer of Virion commented “We are excited to have Drs. Berrey and Bradford join our Board; their diverse and extensive experience in drug development and executive management will be of great value to Virion as we grow and advance our programs into the clinic. Both Bill and Michelle are biotech innovators having been pivotal in the discovery and development of the blockbuster drugs Esbriet® (pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)) and Sovaldi® (sofosbuvir for hepatitis C virus), respectively. I’d like to thank Dr. Wright for her contributions and leadership while serving on our Board for the past 3 years.”
M. Michelle Berry, M.D., M.P.H.
Dr. Berrey is currently President, Research and Development and Chief Medical Officer at Intercept Pharmaceuticals. Prior to joining Intercept, she was President and Chief Executive Officer at Chimerix and previously served as Chief Medical Officer at Pharmasset from 2007 to 2012, prior to its acquisition by Gilead. While at Pharmasset, she played a critical role in the development of Sovaldi® (sofosbuvir), which established a transformational new treatment paradigm for patients with hepatitis C. Before joining Pharmasset, Dr. Berrey was Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at. GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey received her M.D. from the Medical College of Georgia and a Master of Public Health from Emory University.
“I am excited to be joining Virion’s Board as VRON-0200 is advancing into the clinic. The proposed program in patients with chronic Hepatitis B Virus infection could represent a significant advance in this therapeutic area if preclinical results translate to humans in the upcoming clinical studies,” said Dr. Berrey.
Bill Bradford, M.D., Ph.D.
Dr. Bradford is an executive, scientist, and advisor with over 20 years of experience in the biopharmaceutical industry. Most recently he was Founder, Director, and Chief Medical Officer of Indalo Therapeutics and previously served at multiple companies including InterMune, where he successfully developed Esbriet® for IPF, and Genentech. Earlier he practiced as an infectious disease specialist at UCSF for 10 years.
“I am a big advocate for disruptive technologies that can alter standard of care treatment paradigms and substantially improve patient outcomes – Virion’s technologies and development programs have the potential to do just that” said Dr. Bradford. “I look forward to helping the Company grow at this exciting time in their history.”
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.